Abivax S.A. (ABVX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Paris, France. The current CEO is Didier Blondel.
ABVX has IPO date of 2023-10-20, 69 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $8.25B.
Abivax S.A. is a French biopharmaceutical company focused on discovering and developing drugs for inflammatory diseases, infectious diseases, and cancer. The company's lead candidate, ABX464, is in Phase IIb clinical trials for ulcerative colitis and Crohn's disease, with additional Phase IIa development for rheumatoid arthritis and completed Phase IIa trials for HIV viral remission. Abivax also develops ABX196, an immune-enhancing therapeutic in Phase 1/2 trials for hepatocellular carcinoma, alongside ongoing research programs targeting dengue fever, influenza, and respiratory syncytial virus. The company operates through partnerships with leading French research institutions including the French National Centre for Scientific Research, University of Montpellier, and Institut Curie. Founded in 2013 and headquartered in Paris, Abivax is advancing a diversified pipeline of novel immunotherapeutic candidates.
